Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OBI PharmaROCO:4174 +3.70%43 PB Ratio is 2.05 as of Jul. 15, 2026, which is 57% below its 10-year median of 4.79. GuruFocus rates ROCO:4174 with a GF Score™ of 43/100 and a GF Value™ of NT$138.61 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,228 Biotechnology companies, OBI Pharma ranks better than 63.84% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), OBI Pharma's share price is NT$29.45. OBI Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was NT$14.35. Hence, OBI Pharma's PB Ratio of today is 2.05.
The historical rank and industry rank for OBI Pharma's PB Ratio or its related term are showing as below:
ROCO:4174'
s PB Ratio Range Over the Past 10 Years
Min: 1.85 Med: 4.79 Max: 12.9
Current: 2.04
During the past 13 years, OBI Pharma's highest PB Ratio was 12.90. The lowest was 1.85. And the median was 4.79.
ROCO:4174's PB Ratio is ranked better than 63.84% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs ROCO:4174: 2.04
During the past 12 months, OBI Pharma's average Book Value Per Share Growth Rate was -50.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -29.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -12.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of OBI Pharma was 91.70% per year. The lowest was -29.10% per year. And the median was -6.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
OBI Pharma PB Ratio Related Terms
OBI Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for OBI Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4174 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, OBI Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OBI Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OBI Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where OBI Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
OBI Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
OBI Pharma (ROCO:4174) has a PB Ratio of 2.05 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OBI Pharma and its competitors. This is 57% below median its historical median of 4.79. Over the past decade, OBI Pharma's PB Ratio has ranged from 1.85 to 12.90. According to the industry distribution chart, OBI Pharma ranks #444 out of 1228 companies in the Biotechnology industry, placing it in the top 36.2%.
Is OBI Pharma's PB Ratio too high?
OBI Pharma's current PB Ratio of 2.05 is 57% below median its 10-year median of 4.79. Over the past 10 years, this metric has ranged from a low of 1.85 to a high of 12.90. The Biotechnology industry median PB Ratio is 2.90. OBI Pharma's value of 2.05 is 29.2% below this industry median. Based on the distribution chart, OBI Pharma ranks #444 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OBI Pharma has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OBI Pharma ranks #444 out of 1228 companies for PB Ratio. This puts OBI Pharma in the upper half of its industry. The industry median PB Ratio is 2.90. OBI Pharma's value of 2.05 is 29.2% below this benchmark. Historically, OBI Pharma's own PB Ratio has ranged from 1.85 to 12.90 over the past decade. While the company's 10-year median is 4.79 vs. the industry median of 2.90, OBI Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OBI Pharma's current PB Ratio of 2.05 is 29.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on OBI Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OBI Pharma's current PB Ratio is 2.05, which is 57% below median its own 10-year median of 4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.61, compared to a current price of NT$29.45 — trading 78.8% below its estimated fair value. The current PB Ratio is 2.05, which is 57% below median its 10-year median of 4.79 and 29.2% below the Biotechnology industry median of 2.90. OBI Pharma's overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current PB Ratio is 2.05 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OBI Pharma (ROCO:4174) Overvalued in 2026?
Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued.
The current stock price of NT$29.45 is trading 78.8% below its estimated GF Value™ of NT$138.61.
GuruFocus considers OBI Pharma to be Possible Value Trap.
Key valuation signals for ROCO:4174:
PB Ratio: 2.05 (57% below median its 10-year median of 4.79)
GF Value™: NT$138.61 vs. price of NT$29.45 (78.8% below fair value)
Industry Position: 29.2% below the Biotechnology median (#444 of 1228)
No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
43GF Score
Get the complete analysis for ROCO:4174
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4174 has been successfully added to your 
